RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

Luis Paz-Ares,David R. Spigel,Christoph C. Zielinski,Yuanbin Chen,Maria Jove,Oscar Juan Vidal,David Chu,Patricia Rich,Theresa M Hayes,M Vanesa Gutierrez Calderon,Reyes Bernabe Caro,Alejandro Navarro,Afshin Dowlati,Bin Zhang,Yan Moore,Haofei Tiffany Wang,Natalya Nazarenko,Santiago Ponce-Aix,Paul A. Bunn

RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

2019

Luis Paz-Ares
David R. Spigel
Christoph C. Zielinski
Yuanbin Chen
Maria Jove
Oscar Juan Vidal
David Chu
Patricia Rich
Theresa M Hayes
M Vanesa Gutierrez Calderon
Reyes Bernabe Caro
Alejandro Navarro
Afshin Dowlati
Bin Zhang
Yan Moore
Haofei Tiffany Wang
Natalya Nazarenko
Santiago Ponce-Aix
Paul A. Bunn

8562Background: Nal-IRI is investigated as monotherapy in patients with SCLC who progressed on or after platinum regimen. The RESILIENT study is a Part 1 study of a Phase 2/3 trial to assess safety...

Keywords:

Cell
Lung cancer
Oncology
Irinotecan liposome
Pathology
Regimen
Internal medicine
Medicine
in patient
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations